---
title: Two Patients with Therapy-Resistant Pemphigus Vulgaris and Severe Underlying
  Disease Showing Good Response to a New IVIg Preparation
date: '2025-01-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39751746/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250103170653&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Pemphigus vulgaris is a severe and often therapy-resistant bullous autoimmune
  disease. Standard therapy with steroids often administered together with another
  immunosuppressant does not respond in all patients or may not be a good therapeutic
  option in patients with severe underlying diseases. Intravenous immunoglobulins
  (IVIgs) represent a treatment alternative, often showing a rapid response which
  allows one to reduce concomitant immunosuppression. Here, we report on two patients
  with ...
disable_comments: true
---
Pemphigus vulgaris is a severe and often therapy-resistant bullous autoimmune disease. Standard therapy with steroids often administered together with another immunosuppressant does not respond in all patients or may not be a good therapeutic option in patients with severe underlying diseases. Intravenous immunoglobulins (IVIgs) represent a treatment alternative, often showing a rapid response which allows one to reduce concomitant immunosuppression. Here, we report on two patients with ...